3OSK
 
 | | Crystal structure of human CTLA-4 apo homodimer | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Cytotoxic T-lymphocyte protein 4, GLYCEROL | | 著者 | Yu, C, Sonnen, A.F.-P, Ikemizu, S, Stuart, D.I, Gilbert, R.J.C, Davis, S.J. | | 登録日 | 2010-09-09 | | 公開日 | 2010-12-08 | | 最終更新日 | 2023-11-01 | | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | | 主引用文献 | Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor triggering
J.Biol.Chem., 286, 2011
|
|
3JV9
 | | The structure of a reduced form of OxyR from N. meningitidis | | 分子名称: | CHLORIDE ION, Transcriptional regulator, LysR family | | 著者 | Sainsbury, S, Ren, J, Stuart, D.I, Owens, R.J, Oxford Protein Production Facility (OPPF) | | 登録日 | 2009-09-16 | | 公開日 | 2010-06-16 | | 最終更新日 | 2011-07-13 | | 実験手法 | X-RAY DIFFRACTION (2.39 Å) | | 主引用文献 | The structure of a reduced form of OxyR from Neisseria meningitidis
Bmc Struct.Biol., 10, 2010
|
|
3JB4
 | | Structure of Ljungan virus: insight into picornavirus packaging | | 分子名称: | VP0, VP1, VP3 | | 著者 | Zhu, L, Wang, X.X, Ren, J.S, Porta, C, Wenham, H, Ekstrom, J.-O, Panjwani, A, Knowles, N.J, Kotecha, A, Siebert, A, Lindberg, M, Fry, E.E, Rao, Z.H, Tuthill, T.J, Stuart, D.I. | | 登録日 | 2015-07-21 | | 公開日 | 2015-10-21 | | 最終更新日 | 2019-12-18 | | 実験手法 | ELECTRON MICROSCOPY (3.8 Å) | | 主引用文献 | Structure of Ljungan virus provides insight into genome packaging of this picornavirus.
Nat Commun, 6, 2015
|
|
3KYJ
 | | Crystal structure of the P1 domain of CheA3 in complex with CheY6 from R. sphaeroides | | 分子名称: | CheY6 protein, Putative histidine protein kinase, SODIUM ION | | 著者 | Bell, C.H, Porter, S.L, Armitage, J.P, Stuart, D.I. | | 登録日 | 2009-12-06 | | 公開日 | 2010-02-16 | | 最終更新日 | 2024-03-20 | | 実験手法 | X-RAY DIFFRACTION (1.4 Å) | | 主引用文献 | Using structural information to change the phosphotransfer specificity of a two-component chemotaxis signalling complex
Plos Biol., 8, 2010
|
|
3KYI
 | | Crystal structure of the phosphorylated P1 domain of CheA3 in complex with CheY6 from R. sphaeroides | | 分子名称: | CheY6 protein, Putative histidine protein kinase | | 著者 | Bell, C.H, Porter, S.L, Armitage, J.P, Stuart, D.I. | | 登録日 | 2009-12-06 | | 公開日 | 2010-02-16 | | 最終更新日 | 2023-11-01 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Using structural information to change the phosphotransfer specificity of a two-component chemotaxis signalling complex
Plos Biol., 8, 2010
|
|
3ME4
 | | Crystal structure of mouse RANK | | 分子名称: | ACETATE ION, CHLORIDE ION, GLYCEROL, ... | | 著者 | Walter, S.W, Liu, C, Zhu, X, Wu, Y, Owens, R.J, Stuart, D.I, Gao, B, Ren, J. | | 登録日 | 2010-03-31 | | 公開日 | 2010-06-02 | | 最終更新日 | 2023-11-01 | | 実験手法 | X-RAY DIFFRACTION (2.01 Å) | | 主引用文献 | Structural and Functional Insights of RANKL-RANK Interaction and Signaling.
J.Immunol., 2010
|
|
3ME2
 | | Crystal structure of mouse RANKL-RANK complex | | 分子名称: | CHLORIDE ION, SODIUM ION, Tumor necrosis factor ligand superfamily member 11, ... | | 著者 | Walter, S.W, Liu, C.Z, Zhu, X.K, Wu, Y, Owens, R.J, Stuart, D.I, Gao, B, Ren, J. | | 登録日 | 2010-03-31 | | 公開日 | 2010-06-02 | | 最終更新日 | 2023-11-01 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Structural and Functional Insights of RANKL-RANK Interaction and Signaling.
J.Immunol., 2010
|
|
7ZFB
 | | SARS-CoV-2 Omicron RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Nanobody C1, Omi-18 heavy chain, ... | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (3.08 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF3
 | | SARS-CoV-2 Omicron RBD in complex with Omi-3 and EY6A Fabs | | 分子名称: | EY6A heavy chain, EY6A light chain, GLYCEROL, ... | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (3.15 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF8
 | | SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab | | 分子名称: | COVOX-150 heavy chain, COVOX-150 light chain, Spike protein S1 | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (2.95 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF5
 | | SARS-CoV-2 Omicron RBD in complex with Omi-12 and Beta-54 Fabs | | 分子名称: | Beta-54 heavy chain, Beta-54 light chain, Omi-12 heavy chain, ... | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (5.32 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZFE
 | | SARS-CoV-2 Omicron RBD in complex with Omi-32 Fab and nanobody C1 | | 分子名称: | Nanobody C1, Omi-32 heavy chain, Omi-32 light chain, ... | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (3.25 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF7
 | | SARS-CoV-2 Omicron BA.2 RBD in complex with ACE2 | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Processed angiotensin-converting enzyme 2, Spike protein S1, ... | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (3.46 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZFF
 | | Omi-42 Fab | | 分子名称: | GLYCEROL, Omi-42 Heavy chain, Omi-42 light chain | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (2.32 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZFD
 | | SARS-CoV-2 Omicron RBD in complex with Omi-25 Fab | | 分子名称: | Omi-25 heavy chain, Omi-25 light chain, Spike protein S1 | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (3.39 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF6
 | | Omi-12 Fab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CITRIC ACID, GLYCEROL, ... | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (2.21 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZFC
 | | SARS-CoV-2 Beta RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs | | 分子名称: | Nanobody C1, Omi-18 heavy chain, Omi-18 light chain, ... | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (3.24 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF9
 | | SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab (P21) | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, COVOX-150 heavy chain, COVOX-150 light chain, ... | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-01 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (3.25 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZF4
 | | SARS-CoV-2 Omicron RBD in complex with Omi-9 Fab and nanobody F2 | | 分子名称: | Nanobody F2, Omi-9 heavy chain, Omi-9 light chain, ... | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-08 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (4.18 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7ZFA
 | | SARS-CoV-2 Omicron RBD in complex with Omi-6 and COVOX-150 Fabs | | 分子名称: | COVOX-150 heavy chain, COVOX-150 light chain, Omi-6 heavy chain, ... | | 著者 | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | | 登録日 | 2022-04-01 | | 公開日 | 2022-06-29 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (4.24 Å) | | 主引用文献 | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell, 185, 2022
|
|
7OOK
 | | Bacteriophage PRD1 Major Capsid Protein P3 in complex with CPZ | | 分子名称: | (4S)-2-METHYL-2,4-PENTANEDIOL, 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine, CHLORIDE ION, ... | | 著者 | Duyvesteyn, H.M.E, Peccati, F, Martinez-Castillo, A, Jimenez-Oses, G, Oksanen, H.M, Stuart, D.I, Abrescia, N.G.A. | | 登録日 | 2021-05-27 | | 公開日 | 2022-06-08 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (2.23 Å) | | 主引用文献 | Bacteriophage PRD1 as a nanoscaffold for drug loading
Nanoscale, 13, 2021
|
|
5OAC
 | |
5O5B
 | | Poliovirus type 3 (strain Saukett) stabilized virus-like particle | | 分子名称: | Capsid proteins, VP1, VP2, ... | | 著者 | Bahar, M.W, Kotecha, A, Fry, E.E, Stuart, D.I. | | 登録日 | 2017-06-01 | | 公開日 | 2017-07-12 | | 最終更新日 | 2022-09-21 | | 実験手法 | ELECTRON MICROSCOPY (3.6 Å) | | 主引用文献 | Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine.
Nat Commun, 8, 2017
|
|
5O5P
 | | Poliovirus type 3 (strain Saukett) stabilized virus-like particle in complex with the pocket factor compound GPP3 | | 分子名称: | 1-[5-[4-(ethoxyiminomethyl)phenoxy]-3-methyl-pentyl]-3-pyridin-4-yl-imidazol-2-one, Capsid proteins, VP4, ... | | 著者 | Bahar, M.W, Kotecha, A, Fry, E.E, Stuart, D.I. | | 登録日 | 2017-06-02 | | 公開日 | 2017-07-12 | | 最終更新日 | 2022-09-21 | | 実験手法 | ELECTRON MICROSCOPY (4.1 Å) | | 主引用文献 | Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine.
Nat Commun, 8, 2017
|
|
5OW6
 | | CryoEM structure of recombinant CMV particles with Tetanus-epitope | | 分子名称: | Capsid protein, VP2, VP3, ... | | 著者 | Kotecha, A, Stuart, D.I, Backmann, M. | | 登録日 | 2017-08-30 | | 公開日 | 2017-09-13 | | 最終更新日 | 2024-05-15 | | 実験手法 | ELECTRON MICROSCOPY (4.2 Å) | | 主引用文献 | Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy.
NPJ Vaccines, 2, 2017
|
|
